Journal
SPHINGOLIPIDS IN CANCER
Volume 140, Issue -, Pages 295-325Publisher
ELSEVIER ACADEMIC PRESS INC
DOI: 10.1016/bs.acr.2018.04.015
Keywords
-
Categories
Funding
- NCI NIH HHS [P01 CA203628] Funding Source: Medline
Ask authors/readers for more resources
Sphingosine kinases (SK1 and SK2) are key, druggable targets within the sphingolipid metabolism pathway that promote tumor growth and pathologic inflammation. A variety of isozyme-selective and dual inhibitors of SK1 and SK2 have been described in the literature, and at least one compound has reached clinical testing in cancer patients. In this chapter, we will review the rationale for targeting SKs and summarize the preclinical and emerging clinical data for ABC294640 as the first-in-class selective inhibitor of SK2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available